Mapping 3-year changes in gray matter and metabolism in Aβ-positive nondemented subjects

Neurobiology of Aging

Volumn 36, Issue 11, 2015, Pages 2913-2924

  Araque Caballero, Miguel Ángel ^a   Brendel, Matthias ^a   Delker, Andreas ^a   Ren, Jinyi ^a   Rominger, Axel ^a   Bartenstein, Peter ^a   Dichgans, Martin ^a,b   Weiner, Michael W ^c   Ewers, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Technische Universität München Munich Cluster for Systems Neurology   (Germany)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's; Longitudinal; Multimodal; Multivariate; Neurodegeneration; Neuroimaging

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN MAPPING; BRAIN METABOLISM; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; GRAY MATTER; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDIAL TEMPORAL LOBE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RADIOLOGICAL PARAMETERS; REGION OF INTEREST; TEMPORAL LOBE; ATROPHY; COGNITIVE DEFECT; METABOLISM; PATHOLOGY; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; ATROPHY; COGNITIVE DYSFUNCTION; FEMALE; GLUCOSE; GRAY MATTER; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS;

EID: 84946399308     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.08.007     Document Type: Article

References (43)

1. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007, 38:95-113.
2. Ashburner J., Friston K.J. Unified segmentation. Neuroimage 2005, 26:839-851.
3. Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., Holtzman D.M., Santacruz A., Buckles V., Oliver A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., Sperling R.A., Salloway S., Morris J.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 2012, 367:795-804.
4. Benzinger T.L., Blazey T., Jack C.R., Koeppe R.A., Su Y., Xiong C., Raichle M.E., Snyder A.Z., Ances B.M., Bateman R.J., Cairns N.J., Fagan A.M., Goate A., Marcus D.S., Aisen P.S., Christensen J.J., Ercole L., Hornbeck R.C., Farrar A.M., Aldea P., Jasielec M.S., Owen C.J., Xie X., Mayeux R., Brickman A., McDade E., Klunk W., Mathis C.A., Ringman J., Thompson P.M., Ghetti B., Saykin A.J., Sperling R.A., Johnson K.A., Salloway S., Correia S., Schofield P.R., Masters C.L., Rowe C., Villemagne V.L., Martins R., Ourselin S., Rossor M.N., Fox N.C., Cash D.M., Weiner M.W., Holtzman D.M., Buckles V.D., Moulder K., Morris J.C. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E4502-E4509.
5. Bourgeat P., Chetelat G., Villemagne V.L., Fripp J., Raniga P., Pike K., Acosta O., Szoeke C., Ourselin S., Ames D., Ellis K.A., Martins R.N., Masters C.L., Rowe C.C., Salvado O., Group A.R. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010, 74:121-127.
6. Braak H., Thal D.R., Ghebremedhin E., Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 2011, 70:960-969.
7. Calhoun V.D., Liu J., Adali T. A review of group ICA for fMRI data and ICA for joint inference of imaging, genetic, and ERP data. Neuroimage 2009, 45:S163-S172.
8. Caroli A., Prestia A., Galluzzi S., Ferrari C., van der Flier W.M., Ossenkoppele R., Van Berckel B., Barkhof F., Teunissen C., Wall A.E., Carter S.F., Scholl M., Choo I.H., Grimmer T., Redolfi A., Nordberg A., Scheltens P., Drzezga A., Frisoni G.B. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 2015, 84:508-515.
9. Chetelat G., Villemagne V.L., Villain N., Jones G., Ellis K.A., Ames D., Martins R.N., Masters C.L., Rowe C.C., Grp A.R. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 2012, 78:477-484.
10. Cohen A.D., Price J.C., Weissfeld L.A., James J., Rosario B.L., Bi W., Nebes R.D., Saxton J.A., Snitz B.E., Aizenstein H.A., Wolk D.A., Dekosky S.T., Mathis C.A., Klunk W.E. Basal cerebral metabolism may modulate the cognitive effects of A{beta} in mild cognitive impairment: an example of brain reserve. J. Neurosci. 2009, 29:14770-14778.
11. Cohen J. A power primer. Psychol. Bull. 1992, 112:155-159.
12. Dickerson B.C., Stoub T.R., Shah R.C., Sperling R.A., Killiany R.J., Albert M.S., Hyman B.T., Blacker D., Detoledo-Morrell L. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011, 76:1395-1402.
13. Ewers M., Insel P., Jagust W.J., Shaw L., Trojanowski J.J., Aisen P., Petersen R.C., Schuff N., Weiner M.W. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, Gray matter, and cognitive changes in nondemented subjects. Cereb. Cortex 2012, 22:1993-2004.
14. Ewers M., Sperling R.A., Klunk W.E., Weiner M.W., Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci. 2011, 34:430-442.
15. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
16. Jack C.R., Wiste H.J., Weigand S.D., Knopman D.S., Lowe V., Vemuri P., Mielke M.M., Jones D.T., Senjem M.L., Gunter J.L., Gregg B.E., Pankratz V.S., Petersen R.C. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013, 81:1732-1740.
17. Jagust W.J., Bandy D., Chen K., Foster N.L., Landau S.M., Mathis C.A., Price J.C., Reiman E.M., Skovronsky D., Koeppe R.A. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010, 6:221-229.
18. Jagust W.J., Landau S.M. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J. Neurosci. 2012, 32:18227-18233. Alzheimer's Disease Neuroimaging Initiative.
19. Klunk W.E. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol. Aging 2011, 32(Suppl 1):S20-S36.
20. Knopman D.S., Jack C.R., Wiste H.J. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis. JAMA Neurol. 2013, 70:1030-1038.
21. Knopman D.S., Jack C.R., Wiste H.J., Lundt E.S., Weigand S.D., Vemuri P., Lowe V.J., Kantarci K., Gunter J.L., Senjem M.L., Mielke M.M., Roberts R.O., Boeve B.F., Petersen R.C. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiol. Aging 2014, 35:2096-2106.
22. La Joie R., Perrotin A., Barre L., Hommet C., Mezenge F., Ibazizene M., Camus V., Abbas A., Landeau B., Guilloteau D., de La Sayette V., Eustache F., Desgranges B., Chetelat G. Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia. J. Neurosci. 2012, 32:16265-16273.
23. Landau S.M., Breault C., Joshi A.D., Pontecorvo M., Mathis C.A., Jagust W.J., Mintun M.A. Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J. Nucl. Med. 2013, 54:70-77. Alzheimer's Disease Neuroimaging Initiative.
24. Landau S.M., Harvey D., Madison C.M., Koeppe R.A., Reiman E.M., Foster N.L., Weiner M.W., Jagust W.J. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging 2011, 32:1207-1218. Alzheimer's Disease Neuroimaging Initiative.
25. Landau S.M., Mintun M.A., Joshi A.D., Koeppe R.A., Petersen R.C., Aisen P.S., Weiner M.W., Jagust W.J. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 2012, 72:578-586. Alzheimer's Disease Neuroimaging Initiative.
26. Lowe V.J., Weigand S.D., Senjem M.L., Vemuri P., Jordan L., Kantarci K., Boeve B., Jack C.R., Knopman D., Petersen R.C. Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology 2014, 82:1959-1967.
27. Luders E., Gaser C., Jancke L., Schlaug G. A voxel-based approach to gray matter asymmetries. Neuroimage 2004, 22:656-664.
28. Mattsson N., Insel P.S., Nosheny R., Tosun D., Trojanowski J.Q., Shaw L.M., Jack C.R., Donohue M.C., Weiner M.W. Emerging beta-amyloid pathology and accelerated cortical atrophy. JAMA Neurol. 2014, 71:725-734. Alzheimer's Disease Neuroimaging Initiative.
29. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C., Jagust W., Trojanowski J.Q., Toga A.W., Beckett L. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin. N. Am. 2005, 15:869-877. xi-xii.
30. Muller-Gartner H.W., Links J.M., Prince J.L., Bryan R.N., McVeigh E., Leal J.P., Davatzikos C., Frost J.J. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J. Cereb. Blood Flow Metab. 1992, 12:571-583.
31. Nosheny R.L., Insel P.S., Truran D., Schuff N., Jack C.R., Aisen P.S., Shaw L.M., Trojanowski J.Q., Weiner M.W. Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiol. Aging 2015, 36:273-282.
32. Oh H., Habeck C., Madison C., Jagust W. Covarying alterations in Abeta deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum. Brain Mapp. 2014, 35:297-308.
33. Oh H., Mormino E.C., Madison C., Hayenga A., Smiljic A., Jagust W.J. β-Amyloid affects frontal and posterior brain networks in normal aging. Neuroimage 2011, 54:1887-1895.
34. Petersen R.C., Aisen P., Boeve B.F., Geda Y.E., Ivnik R.J., Knopman D.S., Mielke M., Pankratz V.S., Roberts R., Rocca W.A., Weigand S., Weiner M., Wiste H., Jack C.R. Mild cognitive impairment due to Alzheimer disease in the community. Ann. Neurol. 2013, 74:199-208.
35. Petersen R.C., Aisen P.S., Beckett L.A., Donohue M.C., Gamst A.C., Harvey D.J., Jack C.R., Jagust W.J., Shaw L.M., Toga A.W., Trojanowski J.Q., Weiner M.W. Alzheimer's disease neuroimaging initiative (ADNI): clinical characterization. Neurology 2010, 74:201-209.
36. Rousset O.G., Ma Y., Evans A.C. Correction for partial volume effects in PET: principle and validation. J. Nucl. Med. 1998, 39:904-911.
37. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V.L. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31:1275-1283.
38. Shaffer J.L., Petrella J.R., Sheldon F.C., Choudhury K.R., Calhoun V.D., Coleman R.E., Doraiswamy P.M. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology 2013, 266:583-591.
39. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 2009, 65:403-413.
40. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15:273-289.
41. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., Ames D., Rowe C.C., Masters C.L. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12:357-367.
42. Woo C.W., Krishnan A., Wager T.D. Cluster-extent based thresholding in fMRI analyses: pitfalls and recommendations. Neuroimage 2014, 91:412-419.
43. Wyman B.T., Harvey D.J., Crawford K., Bernstein M.A., Carmichael O., Cole P.E., Crane P.K., DeCarli C., Fox N.C., Gunter J.L., Hill D., Killiany R.J., Pachai C., Schwarz A.J., Schuff N., Senjem M.L., Suhy J., Thompson P.M., Weiner M., Jack C.R. Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimers Dement. 2013, 9:332-337.